Nasal Muco-ciliary Clearance Study With and Without Salt Inhalation

Nasal Muco-ciliary Clearance Study With and Without Salt Inhalation Via a Salt Particle Inhaler at COPD, Asthma and Healthy Individuals

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04189016

Enrollment

Registered

2019-12-06

Start date

2021-02-28

Completion date

2021-09-30

Last updated

2021-01-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obstructive Airway Diseases

Brief summary

Investigating nasal muco-ciliary clearance by scintigraphy

Detailed description

The velocity and the retention of the nasal muco-ciliary clearance is going to be investigated with a salt particle inhaler and a placebo by the method nasal scintigraphy. The hypotheses is that nasal inhalation of salt particles enhance the nasal mucociliary clearance.

Interventions

DEVICEInhalation from a salt particle inhaler with or without content

Inhalation from inhaler with (active) or without (placebo) content

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

OTHER

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* COPD patients (all severities in chronic, stable condition) * Asthma patients (in stable condition without acute asthma symptoms) * Healthy subjects, incl. smokers (no chronic nasal, upper or lower respiratory diseases)

Exclusion criteria

* Age under 18 years * Upper respiratory tract infection / cold within the last 3 weeks and at least 3 weeks must pass from the person has become well to the examination * Allergic / non-allergic rhinitis (hay fever) * Chronic sinusitis * Acute respiratory tract infection in antibiotic therapy * Applied salt inhalation within the past month * Pregnant or breastfeeding women * Nuclear medical examination within the past month * Cannot taste saccharin

Design outcomes

Primary

Measure	Time frame	Description
Nasal Mucociliary Clearance	At study day 1 and 2	Change in nasal mucociliary clearance velocity (mm/min) from placebo to salt inhalation

Secondary

Measure	Time frame	Description
Spirometry	At the beginning and the end of study day 1 and 2	Change in FEV! from placebo to saltinhalation
Saccharin test	At study day 1 and 2	Change in time for saccharin transport

Countries

Denmark

Contacts

Primary ContactZainab Saraj, Cand.Pharm.

zs@liitacare.com0045 22268865

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026